BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38482714)

  • 1. Clonal analysis of metachronous double biliary tract cancers.
    Omori Y; Aoki S; Ono Y; Kokumai T; Yoshimachi S; Sato H; Kusaka A; Iseki M; Douchi D; Miura T; Maeda S; Ishida M; Mizuma M; Nakagawa K; Mizukami Y; Furukawa T; Unno M
    J Pathol; 2024 May; 263(1):113-127. PubMed ID: 38482714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
    Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
    J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
    J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterisation of six human biliary tract cancer cell lines.
    Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
    Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
    Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
    Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metachronous intraductal papillary mucinous neoplasms disseminate via the pancreatic duct following resection.
    Nagai K; Mizukami Y; Omori Y; Kin T; Yane K; Takahashi K; Ono Y; Sugitani A; Karasaki H; Shinohara T; Furukawa T; Hayashi T; Okumura T; Maguchi H; Katanuma A
    Mod Pathol; 2020 May; 33(5):971-980. PubMed ID: 31723240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era.
    D'Andrea MR; Gill CM; Umphlett M; Tsankova NM; Fowkes M; Bederson JB; Brastianos PK; Shrivastava RK
    Oncologist; 2020 May; 25(5):447-453. PubMed ID: 31694894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
    Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
    Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
    J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
    Li YC; Li KS; Liu ZL; Tang YC; Hu XQ; Li XY; Shi AD; Zhao LM; Shu LZ; Lian S; Yan ZD; Huang SH; Sheng GL; Song Y; Liu YJ; Huan F; Zhang MH; Zhang ZL
    Front Immunol; 2022; 13():1049812. PubMed ID: 36389727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.